<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab4">
 <label>Table 4</label>
 <caption>
  <p>Overview of safety outcomes (Safety population)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Adverse events (AEs), n (%)</th>
    <th>BTH1677/
     <break/>Bevacizumab/
     <break/>Carboplatin/Paclitaxel
     <break/>(
     <italic>N</italic> = 59)
    </th>
    <th>Bevacizumab/
     <break/>Carboplatin/
     <break/>Paclitaxel
     <break/>(
     <italic>N</italic> = 30)
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Any AE</td>
    <td>58 (98.3)</td>
    <td>30 (100.0)</td>
   </tr>
   <tr>
    <td>NCI/CTCAE Grade 3 or 4 AEs</td>
    <td>55 (93.2)</td>
    <td>20 (66.7)</td>
   </tr>
   <tr>
    <td>Serious AEs</td>
    <td>24 (40.7)</td>
    <td>13 (43.3)</td>
   </tr>
   <tr>
    <td>BTH1677-related AEs</td>
    <td/>
    <td/>
   </tr>
   <tr>
    <td>Probably related</td>
    <td>13 (22.0)</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>Possibly related</td>
    <td>17 (28.8)</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>AEs leading to discontinuation</td>
    <td>21 (35.6)</td>
    <td>12 (40.0)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Abbreviations: AE</italic> adverse events, 
   <italic>N</italic> overall sample size, 
   <italic>n</italic> number of patients, 
   <italic>NA</italic> not applicable, 
   <italic>NCI/CTCAE</italic> National Cancer Institute Common Terminology Criteria for Adverse Events
  </p>
 </table-wrap-foot>
</table-wrap>
